Variable Corticosteroid Sensitivity of Thymic Cortex and Medullary Peripheral-type Lymphoid Tissue in Myasthenia Gravis Patients: Structural and Functional Effects by WILLCOX, N. et al.
Quarterly Journal of Medicine, New Series 73, No. 271, p. 1071-1087. November 1989
Variable Corticosteroid Sensitivity of
Thymic Cortex and Medullary Peripheral-type
Lymphoid Tissue in Myasthenia Gravis
Patients: Structural and Functional Effects
N. WILLCOX, M. SCHLUEPf, N. SOMMER, D. CAMPANA*,
G. JANOSSY*, A. N. BROWN*, and J. NEWSOM-DAVISf
From the Departments of Neurological Science and * Immunology, Royal Free
Hospital School of Medicine, London NW3 2QG: National Hospital for Nervous
Diseases, Queen Square, London
Accepted 21 April 1989
SUMMARY
The thymus has been studied in myasthenia gravis patients to assess the effects of previous
immunosuppression on total yields of cell suspension, immunohistology and culture responses.
The reduction in cell yields by pretreatment with corticosteroid was very variable. In 16 of 32
cases, cortical, medullary and total cell numbers were all greatly reduced ('depleted cases'),
whereas in the others, they were within or near the typical range for untreated myasthenics.
Cortical thymocytes were even more depleted than precursor thymic blasts. Thus the
interpatient differences in sensitivity to corticosteroid recently described for mature T cells also
affected immature cortical thymocytes and their differentiating medullary progeny.
In the medulla, mature (CD3+) T lymphocytes and germinal centres were enriched by the loss
of cortex and appeared relatively healthy, but somewhat depopulated. Concomitantly, in-vitro
T-cell responses to acetylcholine receptor (AChR) and production of anti-AChR antibody and
total IgG by thymic cells were usually well within the typical range (assessed per 10* cells).
Moreover, the total productivity of the entire thymus was reduced almost entirely by the cellular
depopulation rather than by decreased function per surviving cell. Thus the main actions of this
alternate day therapy with corticosteroids were apparently on total peripheral cell numbers, and
perhaps on activated cells and effector mechanisms too, and its thymic effects were inessential.
INTRODUCTION
There are few reports on the in-vivo effects of corticosteroids on human lymphoid tissues,
and many unanswered questions persist. It is not clear whether these drugs act primarily on
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lymphocyte generation and thus on cell numbers, or on the tissue distribution or functions of
the surviving cells, or on the effector mechanisms in the immunological diseases where they
are so widely used. Corticosteroids are often beneficial, for example, in the autoimmune
disease myasthenia gravis [1], as is thymectomy in young-onset cases [2], but the mechanisms
of both effects are unclear. Furthermore, different subjects vary greatly in the sensitivity of
their peripheral T lymphocytes to corticosteroids [3, 4], and it is important to know which
cell types or tissues express this resistance/susceptibility in man.
In myasthenia gravis, the muscle weakness results from a reduction in the number of
acetylcholine receptors (AChR) at the motor endplate caused by complement-fixing
autoantibodies to them (reviewed in ref. 5). There is a special relationship with the thymus in
myasthenia gravis. About 10 per cent of cases have a thymoma, and among the remainder,
there are 'hyperplastic' changes in the thymic medulla in most young onset patients [6]. As
the rare medullary myoid cells express AChR both in vitro [7] and in situ [8], it has been
suggested that autoreactivity in myasthenia gravis is initiated within the thymus [7].
Some myasthenic patients undergo thymectomy during treatment with corticosteroid,
giving us an unusual opportunity to examine its in-vivo effects. The myasthenia gravis
thymus is particularly suitable for study, (a) because its cortex is one of the most steroid-
sensitive tissues in laboratory animals [9, 10], and is the primary site of T lymphocyte
generation. As in the normal thymus, incoming progenitors identifiable by the nuclear
enzyme terminal deoxynucleotidyl transferase (TdT) generate very large numbers of
immature cortical thymocytes that also express both the CD4 (helper/inducer) and CD8
('cytotoxic/suppressor') T-cell markers. Some of these almost certainly enter the medulla
and differentiate into the mature single CD4+ or CD8+ T lymphocytes that express surface
receptors for antigen (the CD3 complex) and are subsequently exported (ref. 11, reviewed in
ref. 12). Furthermore (b) the myasthenia gravis thymic medulla is invaded by lymph node-
type T cell areas and follicles with germinal centres [13]. These are very similar to those found
in peripheral lymphoid tissues in structure [13] and in culture responsiveness too. Typically,
myasthenia gravis thymus cell suspensions spontaneously synthesize anti-AChR antibody in
vitro at rates that correlate strongly with the serum anti-AChR titre [14, 15]. Many other B
cells are also present in the myasthenia gravis thymus, since pokeweed mitogen often
stimulates production of high levels of total IgG and of antibody to influenza virus, for
example [16]. In contrast, anti-AChR production is selectively activated in vivo, and is
usually depressed by pokeweed mitogen in culture [17, 18].
Hence we have been able to study the effects of corticosteroids on both central and
peripheral-type lymphoid tissues, and on immunohistology and total yields of thymus cells
in suspension as well as on their function, using thymus from 35 myasthenia gravis patients
treated with corticosteroids alone and six with azathioprine as well. All the results have been
compared with those from a control panel of 75 untreated patients with myasthenia gravis.
MATERIALS, METHODS AND PATIENTS
Staining of tissue sections
Approximately 10 to 15 per cent of the thymus was used for routine histopathological
examination, and for unfixed tissue blocks; six pm cryostat sections from the latter were
stained by indirect immunoperoxidase or immunofluorescence techniques as described in
ref. 13. Two separate blocks of thymus from each of 13 patients were analysed by an
immunoperoxidase technique using the same panel of monoclonal antibodies (Mabs) to T, B
and thymic epithelial cell subsets, to follicular dendritic cells, and to HLA-class II, as in ref.
19. Rabbit anti-keratin was from Dakopatts (Denmark).
TABLE 1. Clinical features of the pretreated cases of myasthenia gravis studied
Patient subgroup
(range of
depletion
indices)
Sex Grade of myasthenia gravis Onset Duration Serum
M/F age of myasthenia a-AChR
Pretreatment Thy m us
pathology
Mild Medium Severe (years)} gravis (months)} titre Corticosteroids Azathioprine
(nMol)} Duration Atrophic Normal Hypcrplastic
Dosct
(g)t
Duration (months)
(months)
for
Corticosteroids alone
Non-depleted
(Depiction index)-23.5-17) 4/8 5
Intermediate
(Depletion index 18.0-31.5) 4/2 4
Depicted
(Depletion index 33-86.5) 3/14 3
Corticosteroids + azathioprine
(Depletion index 50.1-83.6) 1/5
Correlation coefficient
vs. depletion index in
cases given corticosteroids alone
28 60
(13-38) (4-360)
19 8.7'
(13-41) (4-75)
25.9 II**
(13-40) (1.5-20)
23 10.5
(15-38) (6-184)
-0 .14 - 0 49***
77 5.6 9.0 0
(3.5-1200) (0.9-41) (1-60)
29 4.8 4 5 0
(0.6-75) (0 9-55) (2-26)
15.7 2 1* 40 0
(0.2-680) (0 1-12.5) (0.2-12)
31.0 3.6 2.9
(3-200) (0 7-9 4) (1-5.5)
3.4
(1-125)
- 0 .27 -0 .29 -0.29
*• Versus non-depleted subgroupp<0.002 by Mann-Whitney U test. */> = 0.05-0 1.
*** Correlation is significant p<0.05.
t Cumulative total doses are given in grams.
} Numbers are medians (range in parentheses.
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Cell suspension studies
Cell suspension was prepared from all the remaining tissue by mechanical disruption [17],
and the total cell yield determined by a single observer. The cells were stained by indirect
immunofluorescence and cultured as described in ref. 17. In most cases, the immunofluores-
cence-stained cells were analysed on an Ortho Systems 50 Fluorescence Activated Cell
Sorter, but in a few by fluorescence microscopy. In some, two-colour immunofluorescence
staining with rabbit antiterminal deoxynucleotidyl transferase (TdT, Seralab) and either
Ki67 (Dakopatts) or anti-CD 1 MAbs was also performed [20]. Laboratory conditions were
standardized throughout as far as possible (using screened batches of fetal calf serum for
cultures, and constant cell concentrations, sources of media, etc.). The radioimmunoassay
for anti-AChR antibodies, and the ELISA assay for total IgG (both in culture supernatants)
are described in ref. 17.
T-cell proliferative responses
Thymus cells, either unseparated or enriched for low density cells, were cultured at 106 cells/
ml (with or without 10 //g/ml of affinity-purified AChR from Torpedo marmorata
electroplax) in triplicate in round-bottomed micro wells [21]. At 72 h, 1 /iCi of 3H thymidine
was added and, 16 h later, the cells were harvested and counted [21].
Patients
The study is based on 41 patients with myasthenia gravis receiving treatment with
immunosuppressive drugs, and a control panel of 75 cases given anticholinesterases alone -
'untreated' - all of whom underwent therapeutic thymectomy. Of the former, 35 were given
corticosteroids alone (mostly on alternate days), and six received azathioprine in addition,
both of which were continued until the time of surgery. Thus the last oral dose was either 24
or 48 h before thymectomy; in addition all received 100 mg hydrocortisone IM one hour
before surgery. Their clinical details are summarized in Table 1, where they are grouped
according to treatment and thymic cell yield. Thymic histology was analysed (by H and E) in
all cases (Table 1), and immunohistology in 13. The 75 'untreated' samples were studied
identically (see refs. 8, 13-19, 21). For a systematic immunohistological study, 40 of these
had been selected to cover a full spectrum of anti-AChR titres and durations of myasthenia
gravis [19]. Seventeen thymic samples from non-myasthenic controls (ranging from four
months to 44 years of age) were taken at cardiothoracic operations.
RESULTS
TOTAL YIELDS OF THYMUS CELL SUSPENSION
The total thymic cell yields from 38 immunosuppressed patients are compared in Fig. 1 with
those from the 75 untreated cases which vary over a broad range, but decline significantly
with age (r = — 0.58,p < 0.001). Yields were 10-fold below this range in the six cases receiving
corticosteroids and azathioprine, and in many given corticosteroids alone (Fig. 1). To
quantitate these reductions, we define a 'depletion index' as the vertical distance of each
point below the regression line for the untreated cases; its scale is logarithmic, a value of 40
being a 10-fold depletion.
Two main findings emerge. First, in the 32 patients who received corticosteroids alone, the
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FIG. 1. Plot of total thymic cell yield (log,0) against age at thymectomy in pretreated and untreated
cases of myasthenia gravis. The regression line for the 75 untreated myasthenics is drawn solid; the
dotted lines at 1.5 standard deviations from it. Comparable points are shown for the 38
immunosuppressed patients tested. A log cell yield of 4.0 = 10 000 x 106 cells. • = Untreated patients; in
the group who received corticosteroid alone, O = non-depleted, C = intermediate, • = depleted.
Group who received corticosteroids plus azathioprine = B.
depletion indices differed from those in the untreated cases and this difference was highly
significant (p«0-001, Mann-Whitney U test). Second, within this group, cell depletions were
strikingly variable. Ten cases fell clearly within the control range (depletion index < 17) and
are designated 'non-depleted'. In 16 others, cell yields were about 10-fold lower (depletion
index > 32) - the 'depleted' cases - and there were six remaining 'intermediates' with
depletion indices of 18 to 31. For easy reference in later Figures, these subgroups have been
given distinctive symbols (Fig. 1).
Total yields of both cortical (CD1+) and medullary (CD1 ~) cells also declined with age in
untreated cases (r= —0.51 and —0.48, p<0.001). In nearly every pretreated case, the
depletion of each of these subsets was very similar to that in Fig. 1 (not shown), and so
therefore were the overall patterns. Cortical cells were more reduced than medullary, but
even the latter were below the untreated range in 19 of the 22 highly depleted cases (i.e. with
depletion indices > 32).
Surprisingly, the depletion index correlated with neither the duration nor the total dose of
corticosteroids (Table 1, bottom row). In four depleted cases, as few as 5 to 21 days of
corticosteroids reduced the yields quite drastically (depletion indices 40,41,58,64), whereas
several non-depleted cases showed minimal effects despite being treated for much longer
(Table 1). In fact the best discriminators between the subgroups proved to be the duration of
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symptoms of myasthenia gravis before the start of treatment or thymectomy, both being
significantly longer in the less depleted cases (Table 1, bottom row).
CORTICAL AND MEDULLARY CELL SUBSETS IN SUSPENSION
Frequencies of cortical thymocytes (CD1+) were 60 to 75 per cent in most untreated thymus
suspensions (Table 2): they were almost zero after treatment with corticosteroids plus
azathioprine (0-10 per cent), and significantly reduced overall in the patients given
corticosteroids alone (p =0.0002, Mann-Whitney U test), especially in the depleted cases
(Table 2). Thus the single CD4+, CD8 + or HLA-class II+ medullary cells were substantially
enriched (see Table 3), as they were somewhat less depleted than the CD1+ thymocytes.
Subsets of cortical thymocytes
The nuclear enzyme terminal deoxynucleotidyl transferase (TdT) is an independent marker
for cortical thymocytes, most of which are TdT+, CD1+ in both the normal [22] and the
untreated myasthenia gravis thymus. Thus of total thymus cells these constituted about 50
per cent (Table 2). This frequency was decreased about 15-fold in the more depleted cases
(depletion index > 32), demonstrating that the TdT+, CD1+ subset was one prime target of
corticosteroids. By contrast, the infrequent large immature thymic blast subpopulation that
expresses greater amounts of nuclear TdT with no membrane CD1 (Fig. 2(a) and (c)) was
TABLE 2. Frequencies of cortical thymocyte subsets in untreated and immunosuppressed
patients with myasthenia gravis: percentage of total thymic cells, expressed as median (range)
Patient group
Untreated
Corticosteroids alone
Non-depleted
Intermediate
Depleted
Corticosteroids plus azathioprine
%CD1 +
68.6
(17-92)
76.1
(6.4-85)
52.0
(7.8-73)
25.8*"
(0-55)
3.4***
(0-19)
n
64
10
6
15
6
%TdT+
60.0
(15-71)
53.0
(20-73)
33.0
(9-75)
5.0**
(< 0.5-33)
2.0**
(< 0.5-5)
%TdT+/CDl +
49.7
(13-67)
40.9
(15-70)
18.8
(5-72)
3.1**
(0.5-23)
0.5**
(< 0.5-4.3)
%TdT+/CDl-
4.5
(0.7-13)
5.6
(2.2-10.1)
4.4
(3.0-6.6)
0.6
(< 0.5-8.2)
0.5*
(0.4-0.7)
n
8
5
5
5
3
**p<0.01 )• versus untreated cases (by Mann-Whitney U test).
***/><0.001.
For the entire group treated with corticosteroid alone, CD1 +, TdT+ and TdT+/CDl+ frequencies
also differ from those in the untreated (/><0.00l, p<0.05, p = 0.05 respectively).
Fresh thymic cells were stained with anti-CDl in as many cases as possible as described in ref. 17. For
labelling for TdT and CD 1, cells that had been preserved in liquid nitrogen were used from all available
treated cases, and from eight untreated patients of representative ages, and were double-labelled as in
ref. 20.
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FIG. 2. Cortical thymus cell subsets in a corticosteroid-depleted patient (depletion index 63.5). (a-c) A
cytocentrifuged smear was double-labelled for TdT (a, TRITC) and CD1 (b, FITC). Two large TdT+,
CD 1 ~ blasts are arrowed; just above the arrows is one small TdT" and one TdT+ cell, both CD 1 +. (d-
Q Another smear was labelled for TdT (d, TRITC), and with Ki67 (e, FITC). Most of the TdT+ cells,
whether small or large, are Ki67+, and thus are still in cycle, despite the depletion after treatment with
corticosteroids. (c) and (Q show phase-contrast illumination: all x 780.
reduced about seven-fold in the same samples (Table 2). Its total yield was decreased too,
though less than that of the TdT+, CD1 + cells.
In selected samples, we also investigated the proliferative activity of thymocyte
subpopulations using the Ki67 MAb, which identifies a nuclear antigen expressed during the
Gi, S, G2 and M phases of the cell cycle [23]. The overall Ki67+ frequency was reduced from
49 and 52 per cent in two untreated cases to 0.2 to 10 per cent in four depleted samples. In
both groups, proliferative activity was virtually confined to cortical cells, more than 95 per
cent of the Ki67+ cells being TdT + . In all samples tested, the proportion of cortical (TdT+)
cells that was in cycle (i.e. Ki67+) was similar - 69 and 79 per cent in the two untreated, 38 to
78 per cent in three non-depleted, 62 to 97 per cent in three intermediate cases, and 62 per
cent in one depleted patient (Fig. 2 (d-f)). Thus the depletion of total cell numbers affected
the Ki67 positive (cycling) and Ki67 negative subsets of cortical cells impartially, and there
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were no obvious cytostatic effects of corticosteroids, even in the less depleted cases. The
results from untreated cases are similar to those from non-myasthenic infant thymus [20].
IMMUNOHISTOLOGICAL FINDINGS
(Our findings in the normal and in the untreated myasthenia gravis thymus are summarized
in refs. 13 and 19.) From pretreated patients 13 samples were available. In three non-depleted
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FIG. 3. Thymus from a patient treated with corticosteroids plus azathioprine (depletion index 56.5).
The same area has been stained in adjacent sections. CD1 + cortical areas (a) are very restricted and
fragmented. Their MR6+ cortical epithelial staining (b) is more extensive, so that some MR6+ patches
are devoid of CD1+ cells. Anti-HLA-DR(c) also labels the T-cell zones and the small germinal centre
near the centre, in addition to the cortical epithelium. All x 75. Immunoperoxidase staining.
cases, immunohistology was essentially normal for the donors' ages, in spite of eight-
months' high-dose treatment in one 14-year-old male. Three further samples (depletion
indices 9.5, 20.5, 47.5) showed mild to moderate hyperplasia typical of myasthenia gravis,
but only slight fragmentation/septal expansion.
The remaining samples were from four depleted patients and three given corticosteroid,
plus azathioprine (depletion indices 56.5-86.5). In all seven there was some medullary
hyperplasia superimposed on a series of changes not seen above. These included epithelial
cysts, greatly enlarged septal/adipose areas and, above all, fragmentation, depletion and
necrosis in cortical areas, leading to a gross loss of normal architecture. Thus CD1 +
lymphoid cells were either confined to small scattered patches (Fig. 3(a)), or were almost
completely absent, in keeping with their low frequencies in suspension (Table 2).
Interestingly, these usually retained some typical network labelling for cortical epithelium
with the anti-class II and especially MR6 Mabs (Figs. 3(b,c)). Staining for keratin was often
weaker, and so the extent of cortical labelling was greatest with MR6 > Class II > keratin »
CD1.
As a result of the depletion of cortex, the medullary epithelial areas, germinal centres and
T-cell zones were greatly enriched and constituted almost all the remaining thymus, the
epithelium sometimes showing the characteristic bands and arches [13, 19]. Furthermore,
these areas usually appeared relatively undamaged, though somewhat depleted of lympho-
cytes. Finally, the only contribution of azathioprine that we could see (beyond those of
corticosteroids alone) was that the depletions were more consistent (cf. ref. 24).
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CULTURE ACTIVITIES OF THYMUS CELLS
Anti-AChR antibody and total IgG were assayed in supernatants of thymus and blood
mononuclear cells after culturing in the presence and absence of pokeweed mitogen. In
untreated cases of myasthenia gravis, these thymic responses are all enriched by removing
cortical thymocytes, e.g. with anti-CDl plus complement in vitro [18]; in this study the
depletion of these cells by corticosteroids in vivo had a similar effect (Table 3). Therefore, to
compare the treated and untreated cases more fairly, we have expressed the results as activity
per 106 medullary (CD1 ~) cells (Fig. 4(a)). We have also summed the total productivity of
the entire thymus in the same cases ( = production per 106 cells x total cell yield, Fig. 4(b)).
Anti-AChR production
In untreated myasthenia gravis, spontaneous anti-AChR production per 106 medullary
thymic cells correlates well with the serum anti-AChR titre (r = 0.69, p< 0.001, Fig. 4(a)).
Notably, in most of the pretreated cases production was clearly within the same range as the
untreated, and the frequencies of producers at different serum anti-AChR titres were similar
or even higher (Fig. 4(a)).
The calculated total anti-AChR productivity of the entire thymus also correlated in
untreated cases with serum anti-AChR titre, as expected (r = 0-57, p< 0.001, Fig. 4(b)).
Many of the 21 highly depleted cases fell below this typical range largely because of the
cellular depopulation. By contrast, almost all the cases in the other subgroups were well
within it (Fig. 4(b))
TABLE 3. Thymic B cell frequencies and culture responses in myasthenia gravis
patient subsets, expressed as median (range)
Patient
group
Untreated
Corticosteroids alone
Non-depleted
Intermediate
Depleted
Corticosteroids + azathioprine
Frequency
B Cells
%
4.75
(0.4-26)
3.1
(1.0-22.9)
8.3
(2.9-20.9)
14.4**'
(0.1-29.6)
2 4 . 1 "
(1.6-29.1)
of
n
62
9
5
14
6
Production of total IgGt
— pokeweed
mitogen
0.2
(0.01-1.9)
0.07
(0.02-5.5)
1.56
(0.01-4.2)
1.5***
(0.04-7.7)
2.0*»*
(0.9-5.9)
+ pokeweed
mitogen
22.1
(0.1-139)
52.4
(0.2-180)
22.7
(1-131)
38.0*
(3-254)
62.0*
(3-370)
n
41
7
5
13
6
*p<0.05
** p<0.01 ^ versus untreated group (Mann-Whitney U test).
•••p<0.001.
t IgG values are in /ig/ml of supernatant per 10* cells cultured for seven days.
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FIG. 4. (a) Plot of in-vitro anti-AChR production by thymus cells against serum anti-AChR titre in
pretreated and untreated cases of myasthenia gravis. The regression line of logio spontaneous anti-
AChR production per 106 medullary (CD1 ~) thymic cells (fmol/ml/week) on log serum anti-AChR
titre (nMol) in 74 untreated myasthenics is drawn solid. Comparable points are shown for the 34
immunosuppressed patients tested. The background of the anti-AChR assay ranges up to 1.4 log units,
(b) Plot of total anti-AChR productivity against scrum anti-AChR titre. The regression line of logio
spontaneous anti-AChR productivity per entire thymus on logio serum anti-AChR titre is shown for
the same patients as in (a). In (a) and (b) the dotted lines and symbols are as in Fig. 1.
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FIG. 5. Plot of logio total IgG productivity against logio total thymic B cell yield in pretreated and
untreated cases of myasthenia gravis. The regression line for untreated patients is drawn solid, the
dotted lines and symbols are as in Fig. 1.
Total IgG production
For untreated myasthenia gravis thymus cells, spontaneous total IgG production correlates
significantly with B cell frequencies [19]. For most treated cases the values (per 106 medullary
cells) were within this 'typical' scatter and were rarely reduced (data not shown). They were
predictably high in some with very numerous B cells but disproportionately so in five others
(Table 3) - possibly a sign of the polyclonal induction of IgG secretion by corticosteroids
observed by others (see ref. 25 for other references). The IgG response to pokeweed mitogen
was likewise rarely decreased after immunosuppression and more often enriched (Table 3).
Summed for the entire thymus, the total spontaneous IgG productivity correlated well
with the total B cell yield in untreated cases (r = 0.62, p< 0.01, Fig. 5). After treatment, the
scatter was greater: both IgG and B cell yields tended to be low in the 19 most depleted cases
where only five overlapped with the untreated ones. In general, the same held true for IgG
productivity stimulated by pokeweed mitogen (not shown).
T cell responses to A ChR
Proliferative responses to Torpedo AChR in thymus samples from untreated myasthenics
correlated with CD3 + cell frequencies (r = 0.61, p < 0.001), and were highest when these were
enriched in low density fractions (Fig. 6). Responses from eight of the nine pretreated cases
tested were within or above this range, and had evidently been enriched by the cortical
depletion (Fig. 6); total thymic responsiveness decreased with the reduction in cell yields (not
shown).
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FIG. 6. T-cell proliferative responses of pretreated and untreated myasthenia gravis thymic cells to
purified Torpedo AChR plotted against CD3+ frequency (%). The response is expressed as cpm in
cultures with AChR —cpm in cultures without (Acpm). The regression line for the cells of untreated
patients is drawn solid, o Unseparated thymic cells from untreated cases, A LOW density thymic cells
from untreated cases. Unseparated thymic cells from cases treated with corticosteroids. O - non-
depleted; © - intermediate; • - depleted.
RESPONSES OF BLOOD LYMPHOCYTES
Anti-AChR production in untreated cases was only seen in response to pokeweed mitogen,
even when the serum titre exceeded 15 nmol. Among the treated cases, responders were
apparently fewer, but the level of response (when positive) was comparable (not shown).
Basal and pokeweed mitogen-stimulated IgG production were broadly similar in immuno-
suppressed and untreated cases (not shown). However, proliferative responses to Torpedo
AChR were seen in only one of seven cases treated with corticosteroid compared with seven
of 20 untreated (not shown).
Thus in general the major effects of therapy - especially in the thymus - were on total cell
numbers and gross productivity: activity per cell was rarely reduced, except possibly with
blood cells.
DISCUSSION
Effects of treatment with corticosteroids on thymic cortex and medulla
In this study, we have exploited an unusual opportunity to investigate the in-vivo effects of
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corticosteroids in man - on thymic structure, and on a range of disease-related and other
cellular functions - in the autoimmune disorder myasthenia gravis. The comparisons
between treated and control tissue have been made possible by our access to thymus from a
large panel of untreated myasthenics. Unlike lymph nodes, the thymus is a self-contained
organ, and cell yields and culture behaviour are consistent and predictable. Furthermore,
our findings provide structural and functional evidence for the resistance of some patients to
this therapy.
The dominant feature in many cases treated with corticosteroids was the necrosis and
depletion of cortical thymocytes, one of the major effects of corticosteroids in experimental
animals, where it may begin within four to 12 hours [9, 10]; it is also a feature of stress- and
poison-induced thymic atrophy both in man and experimental animals (reviewed in ref. 26).
In theory it could be mediated by epithelial cells which also have receptors for steroid
hormones [27]. However, a direct effect on immature thymic blasts and especially on the
cortical thymocytes (usually the most severely depleted cell type) seems more likely. In mice
these are especially susceptible to corticosteroids in vivo [9, 10] and to corticosteroid-
mediated lysis in vitro [28]. In man they are also more metabolically sensitive to
corticosteroids than peripheral T cells [29], and, in both thymoma [30] and non-neoplastic
thymus, they are rapidly and preferentially depleted in vivo as well [31,32 and this paper]. In
view of this rapidity, direct lysis seems the simplest explanation, and this fits well with the
lack of any obvious cytostatic effects; both cycling (Ki67+) and non-cycling cells were
depleted impartially, even in the less depleted cases. Corticosteroid-induced lympholysis
employs a specialized metabolic pathway [33] that can presumably be activated very readily
in the thymic cortex. Conceivably, however, corticosteroids might also delay or arrest cells in
certain phases of the cycle, and thus exert additional cytostatic effects.
As expected, cell types in the medulla were often greatly enriched, since it was usually less
severely depopulated than the cortex, as in rodents [e.g. refs. 9, 10]. Interestingly, however,
absolute medullary cellularities were substantially reduced too in most of our highly depleted
cases - presumably because output from the cortex [11, 12] was diminished. There may also
have been direct actions of corticosteroids in the medulla, and/or a decreased traffic of
circulating cells, which might well explain the depletion of total B cells (Fig. 5).
Effects of corticosteroids on lymphoid function, and likely therapeutic actions in myasthenia
gravis
Whereas in mice germinal centres may be susceptible to corticosteroids, both they and the
adjacent B cells were apparently enriched after treatment (Table 3). Like the T-cell areas,
they appeared relatively undamaged not only by histological but also by functional criteria.
In untreated cases of myasthenia gravis, basal and pokeweed mitogen-stimulated IgG
production correlate best with germinal centre frequencies, and spontaneous anti-AChR
production (and presumably T-cell proliferative responses) with the T-cell areas [19].
Expressed per 106 cells, these four independent activities were largely unimpaired after
treatment, and more often enriched. Hence, the wide range of cell types responsible for these
activities - germinal centre blasts and resting B cells [19], AChR-specific plasma cells [18]
and T cells, as well as accessory cells - clearly persist in spite of treatment with
corticosteroids. Such secondary-type responses are known to be less sensitive to corticoster-
oids than is the initial response to antigen [34], That they are suppressed in vivo, and only
reactivate after liberation from corticosteroids in vitro, seems unlikely in the light of current
knowledge of the effects of alternate day treatment [35].
Thus another major conclusion from our results is that this immunosuppressive therapy
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mainly affected cell numbers rather than function per surviving cell. This presumably applied
in the periphery as well as in the thymic medulla, since the B lineage cells in the myasthenia
gravis thymus are representative of the entire repertoire in the patient [15,36]. This may seem
paradoxical since, in the serum, anti-AChR levels apparently fall more strikingly during
treatment than does total IgG [37, 38], and one might expect a global reduction in cell
numbers to affect both impartially. Perhaps additionally corticosteroids may selectively
affect activated cells, for example by inhibiting IL2 production [39] or the response to it. Such
immunoregulatory actions might explain how the autoimmune response in myasthenia
gravis comes to be preferentially reduced, as it presumably is continually being reactivated
by recurrent release of AChR or AChR-antibody complexes from damaged endplates. By
contrast, serum IgG depends largely on plasma cells (e.g. in bone marrow and spleen [38])
which may be less susceptible to corticosteroids. Finally, corticosteroids can affect the
complement system [40], and may also act in myasthenia gravis by reducing the endplate
damage.
Interpatient variation in sensitivity to corticosteroids
A third major finding has been the great variability in effects between patients, something
regularly seen in clinical practice (e.g. ref. 37), but seldom discussed. Most strikingly, the
depletion indices correlated with neither the duration nor the total dose of corticosteroids.
We cannot wholly exclude non-compliance in individual patients, but it seems unlikely in as
many as 10 (or even 16) out of 32. In fact, our findings agree very well with an important
recent series of reports on steroid resistance of human lymphocytes assessed in vitro. In about
40 per cent of normal subjects, phytohaemagglutinin-stimulated blood T cells release IL2 at
an unusually high rate that is less easily suppressed by in-vitro corticosteroids [41]. These
rates scarcely overlap between susceptible and resistant subjects who remain true to type
over a period of months or years. Moreover, renal transplant recipients who are steroid-
susceptible in this or similar assays are much more likely to have a functioning kidney three
to six months later [3,4]. These individual differences thus affect responses of mature T cells
both in vivo and in culture, and our data suggest that they also apply to very immature
precursor T cells in the thymic cortex.
These differences might have a genetic basis, in view of known differences in sensitivity to
corticosteroids between species [42], mouse strains [43], and patients of different HLA types
(ref. 44; not evident in our 11 HLA typed cases). As the best discriminators between the
subgroups were the durations of symptoms of myasthenia gravis before thymectomy or
immunosuppression, another possibility is that the persistently hyperplastic myasthenia
gravis thymus is more resistant to corticosteroids. Perhaps more likely, patients with long-
standing myasthenia gravis may only be selected for thymectomy after steroid therapy has
failed, and our series may be enriched for such cases.
Whatever the explanation, this variation in sensitivity must significantly influence the
effective dose of corticosteroids, normally determined empirically for each patient. Three
further practical conclusions from this study are that (i) corticosteroids in myasthenia gravis
do not always destroy the thymus which may still therefore warrant removal, (ii) the main
therapeutic action of corticosteroids in myasthenia gravis is on the peripheral immune
system, since they may be very effective in cases who have had previous thymectomy, and (iii)
the depletion of both cortical and medullary T cells is likely to be a major disadvantage of the
intensive treatment with corticosteroids often used after bone marrow transplantation, since
it may prevent proper T-cell reconstitution via the thymus, especially in steroid-sensitive
subjects.
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